MAP2K7 and thyroid cancer: As per current guidelines from the National Comprehensive Cancer Network (NCCN) [4] and consensus statement from the American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology group [7], only patients with progressive or symptomatic RAI-resistant thyroid cancer should be considered for medical therapy; that may be guided by genetic testing [8], such as BRAF V600E mutation (for BRAF &/or MEK inhibitor), RET fusion (for RET inhibitors), NTRK1/2 fusion (for NTRK inhibitors), or ALK fusion (for ALK inhibitor) [4,7].